How do the new RxPONDER results affect your choice of adjuvant therapy for postmenopausal women with HR+/HER2 negative breast cancer and 1-3 positive lymph nodes?

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Moffitt Cancer Center • HR+ • NCI-CCC Breast Tumor Board Question

Would you send an Oncotype RS to determine the role of adjuvant chemotherapy and/or endocrine therapy?

Answer from: Medical Oncologist at Academic Institution

The RxPonder trial results show that in postmenopausal women with 1-3 positive nodes and recurrence scores under or equal to 25, there was no benefit for chemotherapy added to endocrine therapy versus endocrine therapy alone. Whereas, for those with recurrence of 26 or above, I would offer chemother...

Comments

Medical Oncologist at Breastlink Medical Group
Agree with @Charles L. Shapiro. I think what a fut...

Medical Oncologist at University Medical Oncology
How do you look at Mammaprint in view of the above...

Related Questions